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ABSTRACT 
Hunter syndrome or mucopolysaccharidosis (MPS) type II is an X-linked recessive disorder caused by a defect in the 
metabolism of glycosaminoglycans (GAGs). We present a rare case of MPS with a typical presentation of coarse facies, short 
stature, mild mental retardation and absence of corneal clouding. His radiographic findings were suggestive of MPS and 
diagnosis was confirmed by demonstrating deficient Iduronate-2-sulphatase enzyme in plasma. We present this case to 
highlight the distinctive manifestations as well as radiological and definitive diagnostic findings of the Hunter syndrome. 
Key words: Facial Dysmorphism, Hunter Syndrome, Mucopolysaccharidosis, Short Stature 
ucopolysaccharidosis (MPS) is a group of 
hereditary metabolic disorders caused by 
absence, or malfunctioning of the lysosomal 
enzymes essential for breakdown of glycosaminoglycans 
(GAGs) [1]. This leads to collection of GAGs in the cells, 
blood, and connective tissues resulting in progressive 
permanent cellular damage which manifest as facial 
dysmorphism, organomegaly, joint stiffness, contractions, 
pulmonary dysfunction, myocardial enlargement, and 
neurological impairment [1-4]. Hunter syndrome or MPS 
type II is an X-linked recessive disorder caused by 
deficiency of iduronate-2-sulfatase (I2S) enzyme resulting 
in accumulation of dermatan and heparin sulfates in 
various tissues [5]. Treatment is mainly palliative as no 
effective therapy is readily available; however, bone 
marrow transplant and enzyme replacement therapy with 
recombinant human iduronate-2-sulfatase has been 
successfully tried [6]. 
CASE REPORT: 
A 7 yr old male child brought to pediatric outpatient 
department with complaints of was not gaining height and 
joint stiffness with decreased movements of hands and 
legs for past 3 years. Restriction of movements started 
from hands and gradually progressed to involve knee, 
ankle and small joints of toes. Parents felt child was 
apparently well till 3 yr of age, when mother noticed 
gradual distention of abdomen which was not associated 
with pain in abdomen, any urinary complaints or change in 
bowel habits. Abdominal distension was associated with 
breathing difficulty on and off which used to increase in 
lying down posture with no diurnal variation. He also had 
recurrent cough cold and decreased hearing for past 2 yr; 
however, there was no history of hospitalization.  
There was no history of trauma, history of contact with 
tuberculosis, and any deformity in back/spine. There was 
no history of any neurological deterioration, abnormal 
movements or behavior, vision problems or regression of 
milestones. He was the first of two siblings, born out of 
non-consanguineous marriage. His younger brother was 
normal and developing appropriately. His antenatal, natal 
and post-natal history was uneventful. He was completely 
immunized for age and his development was appropriate 
for age except mildly delayed speech. Child can speak in 
short sentences but cannot tell a story. 
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Figure 1-3. Figure 1 – Child with short stature, protuberant abdomen, large head, coarse facies, and stiff joints. Figure 2 – X-
ray hands and pelvis show generalized osteopenia, delayed appearance of carpal centres with short and wide metacarpals and 
phalanges and tapering of metacarpal bones of hands. Figure 3 – X-ray spine (AP and lateral views) shows relative decrease 
of antero-superior height of lumbar vertebrae with central beaking of L1 & L2 and normal intervertebral spaces. 
On examination, child was afebrile, conscious, well 
oriented with stable vitals. He underweight (weight - 14 
kg, <3 SD for age) and short statured (height - 91 cm, <3 
SD for age) with upper and lower segment ratio of 1/1 and 
head circumference of 52.5 cm (50
th
 percentile). He had 
coarse facies, prominent frontal bulge, narrow nostrils, 
short, broad and stubby fingers and lumbar lordosis (figure 
1). He had knock knees, flat foot with inversion, and joint 
stiffness with limitation of extension at knee, ankle, elbow 
and wrist joints. There was no corneal haziness. On 
respiratory system examination, thorax was symmetrical 
but short and narrow with normal breath sounds. 
Cardiovascular system examination was normal except an 
ejection systolic murmur in aortic area. Per abdomen 
examination revealed hepatosplenomegaly. 
His routine laboratory investigations including 
complete hemogram, serum calcium, phosphorus, liver and 
renal function tests were within normal limits. His thyroid 
and lipid profile was also normal. On skeletal survey, 
dysostosis multiplex was present (figure 2 and 3). 
Echocardiography revealed mild aortic regurgitation with 
thickening of valves and moderate mitral regurgitation. CT 
Head findings were also suggestive of inherited metabolic 
disorder. On the basis of clinical and radiological 
examination, probable diagnosis of MPS was made and 
sample was sent for enzyme studies which showed 
deficient activity of I2S enzyme (5.2 nmol/4 hr/ml, normal 
– 167-475). Thus, confirmatory diagnosis of Hunter 
syndrome was made.  
Decongestive treatment was started and cardiology 
opinion was taken for further management. Tympanometry 
of both ears were performed in view of decreased hearing 
which were suggestive of tympanic membrane perforation. 
Further, genetic analysis by peripheral blood culture 
revealed polymorphism with aneuploidy, and other 
abnormalities suggestive of Hunter syndrome such as 
rosette formation, Acrocentric Association, and 
Robertsonian translocation. Counseling of the parents was 
done and management options were explained including 
bone marrow transplant; however, HLA of the sibling 
could not be matched. Other supportive management such 
as physiotherapy to mobilize the joint and hearing aid was 
advised. 
DISCUSSION 
MPS are hereditary progressive disease of degradation of 
GAGs caused by decreased or absent lysosomal enzyme 
activity leading to intercellular deposition of GAG 
fragments. Distended lysosomes get deposited in cells and 
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interfere with cellular functions giving characteristic 
radiological and clinical pictures. Overall incidence of 
MPS is 3.5-4.5/100,000 live births, of which most 
common subtype is type III followed by type I and type II. 
All MPS are autosomal recessive disorders except type II 
MPS (Hunter syndrome) which is X-linked recessive 
disorder caused by deficiency of enzyme I2S [1-3].  
In 80% patients with Hunter syndrome, mutation has 
been identified. It occurs exclusively in males with an 
incidence of approximately 1 in 170,000 live male births 
[2-3]. It has wide clinical spectrum and common clinical 
presentations are coarse facies, short stature, dysostosis 
multiplex, joint stiffness, hepatosplenomegaly, and normal 
to moderate intelligence. Airway involvements, hearing 
impairment, carpal tunnel syndrome and valvular 
dysfunction are other features seen in Hunter syndrome. 
Sparing of cornea and absence of inguinal hernia 
differentiate them from Hurler syndrome. Two forms of 
Hunter syndrome have been described on the basis of the 
length of survival and presence or absence of central 
nervous system (CNS) involvement [3-4].  
Type A is the severe form with an early onset between 
18 months and 4 years of age and life expectancy of 10-15 
years while type B is the milder form where clinical 
features appear in second decade of life with a life 
expectancy of 30–50 years [1-3]. Patients with type A 
Hunter syndrome have severe mental retardation with loss 
of skills and while those of milder form although may 
have mild mental retardation but their intelligence usually 
is normal. Death in both the forms usually occurs due to 
cardiac failure or obstructive airway diseases.  
Cardiovascular manifestations include incompetence of 
the valves, mitral valve prolapse, ischemic heart disease, 
and cadiomegaly resulting in heart failure. Sensorineural 
deafness is a common feature seen in almost all the cases 
of Hunter’s disease. Though corneal clouding is absent in 
patients with Hunter’s disease, retinitis pigmentosa, 
papilledema, and optic atrophy has been noted in some 
cases. Our patient did not have any ophthalmic problem on 
fundoscopy but he had hearing problems [1-3]. 
Clinical diagnosis of MPS can be made on the basis of 
clinical presentation and skeletal survey [4]. Excess 
urinary heparan and dermatan sulfates are suggestive of 
MPS type I, type II, or type VII. However, confirmatory 
diagnosis can only be made by enzyme assay in 
leukocytes, fibroblasts or dried blood spots, and plasma 
samples. Absent or low I2S activity in males is diagnostic 
of Hunter syndrome, if other sulfatase deficiency has been 
ruled out. In our patient also, plasma I2S enzyme activity 
was remarkably reduced confirming the diagnosis of 
Hunter syndrome [5-6]. 
Bone marrow transplantation (BMT) and umbilical 
cord blood transplantation are the potentially curative 
treatment for MPS. However, these are not routinely 
advocated in clinical practice due to high risk profile and 
lack of evidence for efficacy [7]. Secondly, problem of 
HLA matched donor is always there as happened with our 
patient. Enzyme replacement therapy (ERT) has emerged 
as a new treatment and recently the United States and 
European Unions have approved the use of idursulfatase 
(Elaprase), a recombinant human I2S, for the management 
of MPS type II given as weekly intravenous infusion over 
3h at a dose of 0.5 mg/kg [7-9]. However, more studies are 
needed to confirm its long term efficacy and safety [10]. In 
recent years, substrate reduction therapy and gene therapy 
have been rapidly gaining greater recognition as potential 
therapeutic avenues as they may prevent the 
neurodegeneration not affected by ERT [7]. 
However, these definitive treatments are not readily 
available in most of the developing countries and 
supportive management is mainstay of therapy to improve 
the quality of life of these patients such as physiotherapy 
to mobilise the joints, nutritional management, prevention 
and treatment of infections, blood transfusion, and 
management of cardiac and respiratory complications. 
Prenatal diagnosis using amniocentesis and chorionic 
villus sampling should be offered in next pregnancy to 
detect the possibility of a fetus either carrying a copy of 
defective gene or being affected with the disorder. Genetic 
counselling can help parents with a family history of MPS 
to determine if they are carrying the mutated gene [2,3,5].  
CONCLUSION: 
Hunter syndrome (MPS type II) is a multisystem disorder 
which may present with wide spectrum of clinical features. 
With the advent of hematopoietic stem cell transplantation 
and enzyme replacement therapy, there exists a need for 
early diagnosis, better disease recognition, and 
management. Even if definitive treatment is not available, 
appropriate management through a multidisciplinary 
approach can improve the quality of life of these patients. 
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